1Gunasekara NS, Noble S. Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina peetorisM [J]. Drugs, 1999, 57 (2): 261-277.
2Michel MC, Korstanje C, Krauwinkel W, et al . The pharmacokinetic profile of tamsulosin oral controlled absorption system (OCAS) [J]. Eur Urol Suppl, 2005, 4 (2): 15-241.
3Prabakaran D, Singh P, Kanaujia P, et al . Effect of hy2 drophilic polymers on the release of dihiazem hydrochloride from elementary osmotic pumps [J]. Int J Pharm, 2003, 259 (1/2) :173-179.
4Ayer AD, Swanson DR, Kuczynski AL. Dosage form for treating cardiovascular diseases[EB/OL].http : //www.wikipatents.com/ca/ 4950486. html, 1990-08-21.
5Kuczynski AL, Ayer AD, Wong PSL. Oral hypogly-cemic glipizide granulation [EB/OL]. http://www.wikipatents.com/ca/5024843.htnd. 1991-06-18.
6Theeuwes F. Osmotic system for delivering selected beneficial agents having varying degrees of solubility [EB/OL]. http://www.freep- atentsordine.com/4111201.html, 1991-06-18.
7Liu L, Ku J, Khang G. et al. Nifedipine controlled delivery by sandwiched Osmotic tablet system [J]. J controlrelease, 2000, 68 (2): 145-156.
8Sehuhz P, Kleinebudde P. A new muhipartieulate delayed release system. Part Ⅰ. Dissolution properties and release mechanism[J]. J Control Release, 1997, 47 (2): 181-189.
9Schultz P, Tho I, Kleinebudde P. A new multiparticulate delayed release system. Part Ⅱ. Coating formulation and properties of free films[J]. J Control Release, 1997, 47 (2):191-199.
